Developing novel ADC
therapeutics to treat
Our lead program is ETx-22, a Nectin-4-targeting ADC – developed to bring superior efficacy to patients and with potential across a range of hard-to-treat cancers. ETx-22 uses an innovative linker and payload technology to deliver higher efficacy, lower risk of off-target side effects and ability to avoid tumor resistance. It is based on an antibody with unique properties designed to lower on-target side effects.
Emergence Therapeutics is also actively developing a pipeline of further first- or best-in-class ADCs driven by therapeutic need.
About UsRead More >
ScienceRead More >
ExecutionRead More >
PartnersRead More >
Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload) Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to...View Article >
Emergence Therapeutics strengthens leadership team with the appointment of Hatem Azim as Chief Medical Officer
Duisburg, Germany, 7 June 2022. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces the appointment of Hatem Azim, MD, PhD, as Chief Medical Officer (“CMO”), as of 6 June 2022. Dr. Hatem Azim joins Emergence Therapeutics from Pierre Fabre, a...View Article >
Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity Strategy is to become a dominant ADC developer Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment...View Article >